[Congressional Record Volume 167, Number 145 (Tuesday, August 10, 2021)]
[Senate]
[Page S6393]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 3659. Mr. RUBIO submitted an amendment intended to be proposed by 
him to the concurrent resolution S. Con. Res. 14, setting forth the 
congressional budget for the United States Government for fiscal year 
2022 and setting forth the appropriate budgetary levels for fiscal 
years 2023 through 2031; which was ordered to lie on the table; as 
follows:

       At the appropriate place in title IV, add the following:

     SEC. 4___. POINT OF ORDER AGAINST LEGISLATION THAT WOULD 
                   AUTHORIZE FEDERAL FUNDING FOR COLLABORATIVE 
                   BASIC RESEARCH PROJECTS CONDUCTED BETWEEN THE 
                   UNITED STATES AND CHINA INVOLVING SYNTHETIC 
                   BIOLOGY OR GAIN-OF-FUNCTION STUDIES OF ANY 
                   POTENTIAL HUMAN PATHOGEN.

       (a) Point of Order.--It shall not be in order in the Senate 
     to consider any bill, joint resolution, motion, amendment, 
     amendment between the Houses, or conference report that 
     authorize Federal funding for collaborative basic research 
     projects conducted between individuals or institutions in the 
     United States and individuals or institutions in the People's 
     Republic China involving synthetic biology or gain-of-
     function studies of any potential human pathogen.
       (b) Waiver and Appeal.--Subsection (a) may be waived or 
     suspended in the Senate only by an affirmative vote of three-
     fifths of the Members, duly chosen and sworn. An affirmative 
     vote of three-fifths of the Members of the Senate, duly 
     chosen and sworn, shall be required to sustain an appeal of 
     the ruling of the Chair on a point of order raised under 
     subsection (a).
                                 ______